参考文献/References:
[1].Virani SS,Alonso A,Aparicio HJ,et al. Heart disease and stroke statistics—2021 update:a report from the American Heart Association[J]. Circulation,2021,143(8):e254-e743.
[2].Hao G,Wang X,Chen Z,et al. Prevalence of heart failure and left ventricular dysfunction in China:the China hypertension survey,2012—2015[J]. Eur J Heart Fail,2019,21(11):1329-1337.
[3].Tsutsui H,Ide T,Ito H,et al. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. J Card Fail,2021,27(12):1404-1444.
[4].Singh JP,Cha YM,Lunati M,et al. Real-world behavior of CRT pacing using the AdaptivCRT algorithm on patient outcomes:effect on mortality and atrial fibrillation incidence[J]. J Cardiovasc Electrophysiol,2020,31(4):825-833.
[5].Abdelrahman M,Subzposh FA,Beer D,et al. Clinical outcomes of his bundle pacing compared to right ventricular pacing[J]. J Am Coll Cardiol,2018,71(20):2319-2330.
[6].Kusumoto FM,Schoenfeld MH,Barrett C,et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Circulation,2019,140(8):e506-e508.
[7].Zhang W,Huang J,Qi Y,et al. Cardiac resynchronization therapy by left bundle branch area pacing in patients with heart failure and left bundle branch block[J]. Heart Rhythm,2019,16(12):1783-1790.
[8].Upadhyay GA,Vijayaraman P,Nayak HM,et al. His corrective pacing or biventricular pacing for cardiac resynchronization in heart failure[J]. J Am Coll Cardiol,2019,74(1):157-159.
[9].Huang W,Wu S,Vijayaraman P,et al. Cardiac resynchronization therapy in patients with nonischemic cardiomyopathy using left bundle branch pacing[J]. JACC Clin Electrophysiol,2020,6(7):849-858.
[10].Mack MJ,Lindenfeld J,Abraham WT,et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure[J]. J Am Coll Cardiol,2021,77(8):1029-1040.
[11].Iung B,Armoiry X,Vahanian A,et al. Percutaneous repair or medical treatment for secondary mitral regurgitation:outcomes at 2?years[J]. Eur J Heart Fail,2019,21(12):1619-1627.
[12].Fiore A,Avtaar Singh SS,Nappi F. Learning from controversy and revisiting the randomized trials of secondary mitral regurgitation[J]. Rev Cardiovasc Med,2022,23(3):88.
[13].Li W,Long YL,Pan WZ,et al. Transcatheter edge to edge repair using the ease-of-use valve clamp system for functional mitral regurgitation:a primary report[J]. Surg Today,2023,53(1):90-97.
[14].Liu XB,Chen M,Han YL,et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation[J]. JACC Asia,2022,2(3):390-394.
[15].Webb JG,Pasupati S,Humphries K,et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis[J]. Circulation,2007,116(7):755-763.
[16].Dong M,Wang LZ,Tse G,et al. Effectiveness and safety of transcatheter aortic valve replacement in elderly people with severe aortic stenosis with different types of heart failure[J]. BMC Cardiovasc Disord,2023,23(1):34.
[17].O’Neill WW,Kleiman NS,Moses J,et al. A prospective,randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention:the PROTECT Ⅱ study[J]. Circulation,2012,126(14):1717-1727.
[18].O’Neill WW,Anderson M,Burkhoff D,et al. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices:Impella-supported high-risk percutaneous coronary intervention in patients with severely depressed LVEF[J]. Am Heart J,2022,248(19):139-149.
[19].Wernly B,Seelmaier C,Leistner D,et al. Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock-a critical appraisal of current data[J]. Clin Res Cardiol,2019,108(11):1249-1257.
[20].Kirklin JK,Naftel DC,Pagani FD,et al. Seventh INTERMACS annual report :15,000 patients and counting[J]. J Heart Lung Transplant,2015,34(12):1495-1504.
[21].Kinugawa K,Nishimura T,Toda K,et al. The second official report from Japanese registry for mechanical assisted circulatory support (J-MACS):first results of bridge to bridge strategy[J]. Gen Thorac Cardiovasc Surg,2020,68(2):102-111.
[22].Cho SM,Floden D,Wallace K,et al. Long-term neurocognitive outcome in patients with continuous flow left ventricular assist device[J]. JACC Heart Fail,2021,9(11):839-851.
[23].Bujo C,Amiya E,Hatano M,et al. Long-term renal function after implantation of continuous-flow left ventricular assist devices:a single center study[J]. Int J Cardiol Heart Vasc,2021,37:100907.
[24].Wong ASK,Sin SWC.Short-term mechanical circulatory support (intra-aortic balloon pump,Impella,extracorporeal membrane oxygenation,TandemHeart):a review[J]. Ann Transl Med,2020,8(13):829.
[25].Nso N,Nassar M,Lakhdar S,et al. Comparative assessment of transvenous versus subcutaneous implantable cardioverter-defibrillator therapy outcomes:an updated systematic review and meta-analysis[J]. Int J Cardiol,2022,349:62-78.
[26].Al-Khatib SM,Stevenson WG,Ackerman MJ,et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm,2018,15(10):e73-e189.
[27].Shah SJ,Feldman T,Ricciardi MJ,et al. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF Ⅰ) trial[J]. JAMA Cardiology,2018,3(10):968-977.
[28].Shah SJ,Borlaug BA,Chung ES,et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF Ⅱ):a randomised,multicentre,blinded,sham-controlled trial[J]. Lancet,2022,399(10330):1130-1140.
[29].Rodés-Cabau J,Bernier M,Amat-Santos IJ,et al. Interatrial shunting for heart failure:early and late results from the first-inhuman experience with the V-wave system[J]. JACC Cardiovasc Interv,2018,11(22):2300-2310.
[30].Paitazoglou C,?zdemir R,Pfister R,,et al. The AFR-PRELIEVE trial:a prospective,non- randomised,pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction[J]. EuroIntervention,2019,15(5):403-410.
[31].廖曼,尚小珂,张长东,等. 心房分流术治疗心力衰竭的研究进展[J]. 临床心血管病杂志,2020,36(3):222-227.
[32].Simard T,Labinaz M,Zahr F,et al. Percutaneous atriotomy for levoatrial-to-coronary sinus shunting in symptomatic heart failure:first-in-human experience[J]. JACC Cardiovasc Interv,2020,13(10):1236-1247.
[33].Thomas M,Nienaber CA,Ince H,et al. Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure:one-year primary endpoint results of PARACHUTE III,a European trial[J]. EuroIntervention,2015,11(6):710-717.
[34].Rao IV,Burkhoff D. Cardiac contractility modulation for the treatment of moderate to severe HF[J]. Expert Rev Med Devices,2021,18(1):15-21.
[35].Seferovic PM,Ponikowski P,Anker SD,et al. Clinical practice update on heart failure 2019:pharmacotherapy,procedures,devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2019,21(10):1169-1186.
[36].Abraham WT,Nademanee K,Volosin K,et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure[J]. J Card Fail,2011,17(9):710-717.
[37].Rosalia L,Ozturk C,Shoar S,et al. Device-based solutions to improve cardiac physiology and hemodynamics in heartfailure with preserved ejection fraction[J]. JACC Basic Transl Sci,2021,6(9-10):772-795.
[38].Konstam MA,Udelson JE,Butler J,et al.?Udelson,J.?Butler,et al. Impact of autonomic regulation therapy in patients with heart failure:ANTHEM-HFrEF pivotal study design[J]. Circ Heart Fail,2019,12(11):e005879.
[39].DiCarlo LA,Libbus I,Kumar HU,et al. Autonomic regulation therapy to enhance myocardial function in heart failure patients:the ANTHEM-HFpEF study[J]. ESC Heart Fail,2018,5(1):95-100.
[40].Abraham WT, Zile MR, Weaver FA,et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J]. JACC Heart Fail,2015,3(6):487-496.
[41].Zile MR,Lindenfeld J,Weaver FA,et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction[J]. J Am Coll Cardiol,2020,76(1):1-13.
[42].Zile MR,Abraham WT,Lindenfeld J,et al. First granted example of novel FDA trial design under expedited access pathway for premarket approval:BeAT-HF[J]. Am Heart J,2018,204:139-150.
[43].Li M,Ma W,Fan FF,et al. Renal denervation in management of heart failure with reduced ejection fraction:a systematic review and meta-analysis[J]. J Cardiol,2023,81(6):513-521.
[44].Xu H,Jiang ZX,Jiang WY,et al. The effect of renal denervation on cardiac diastolic function in patients with hypertension and paroxysmal atrial fibrillation[J]. Evid Based Complement Alternat Med,2022,2022:2268591.
[45].Kresoja KP,Rommel KP,Fengler K,et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail,2021,14(3):e007421.
[46].Costanzo MR,Ponikowski P,Coats A,et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure[J]. Eur J Heart Fail,2018,20(12):1746-1754.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]董震宇 穆耶赛尔·玉苏普 芦颜美 汤宝鹏.介入器械治疗慢性心力衰竭的研究进展[J].心血管病学进展,2023,(12):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]
DONG Zhenyu,Muyassar·Yusup,LU Yanmei,et al.Device-based Interventional Strategies for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(8):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]